Offering's proceeds slated to fund the Androxal and Proellex programs
By Devika Patel
Knoxville, Tenn., Sept. 12 - Repros Therapeutics Inc. gave further details about a $23.6 million private placement of stock in an 8-K filed Wednesday with the Securities and Exchange Commission. The deal priced Aug. 31 and settled Sept. 7.
The company sold 2,145,636 common shares at $11.00 per share. The price per share is a 12.7% discount to the Aug. 30 closing share price of $12.60.
Investors were Alta Partners Management VIII, LLC, Baker Bros. Advisors LLC, OrbiMed Capital LLC, Quogue Capital LLC, QVT Associates GP LLC, VenBio Select Fund LLC and VHCP Management, LLC.
Proceeds will be used for the company's Androxal and Proellex programs.
Repros Therapeutics develops drugs for the treatment of reproductive disorders. The company is based in The Woodlands, Texas.
| Issuer: | Repros Therapeutics Inc.
|
| Issue: | Common shares
|
| Amount: | $23,601,996
|
| Units: | 2,145,636
|
| Price: | $11.00
|
| Warrants: | No
|
| Investors: | Alta Partners Management VIII, LLC, Baker Bros. Advisors LLC, OrbiMed Capital LLC, Quogue Capital LLC, QVT Associates GP LLC, VenBio Select Fund LLC and VHCP Management, LLC
|
| Pricing date: | Aug. 31
|
| Settlement date: | Sept. 7
|
| Stock symbol: | Nasdaq: RPRX
|
| Stock price: | $12.60 at close Aug. 30
|
| Market capitalization: | $223.68 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
